Cargando…

持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察

OBJECTIVE: To observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM)with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP). METHODS: From January 2005 to Septembe...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342521/
https://www.ncbi.nlm.nih.gov/pubmed/25854459
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.03.003
_version_ 1783555509365768192
collection PubMed
description OBJECTIVE: To observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM)with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP). METHODS: From January 2005 to September 2013, a total of 75 patients were treated by metronomic chemotherapy with continuous low-dose cyclophosphamide (50 mg/d) and prednisone (15 mg/d). RESULTS: Among the 75 patients, 2 were lost for follow-up. In the 73 available patients, the overall response was 64.4%, including 2 patients (2.7%) with complete remission (CR), 4 cases (5.5%) very good partial remission (VGPR), and 24 patients (32.9%) partial remission (PR). The median survival was 12 months (1–70 months) with a median onset time of 90 days (16–120) and a median progressive freedom survival of 12 months (1–60). The level of B-type natriuretic peptide in responders declined significantly, as compared to no responders [(336.6±30.3) ng/L vs (906.4±104.8) ng/L, P<0.01]. Common adverse events were as follows: 32 (43.8%) cases of bone marrow suppression, 26 (35.6%) cases of infection, 8 cases of dizzy as well as sleepiness (11.0%), 7 (9.6%) cases of Cushing syndrome, 4 (5.5%) cases of secondary diabetes mellitus, and 3 (4.1%) cases of edema respectively. CONCLUSION: The metronomic chemotherapy of cyclophosphamide combined with prednisone had satisfactory impact on the treatment outcome, including the improvement of cardiac functions and physical capacities, better survival and safety in refractory MM with serious heart failure. It provides a novel regimen for such patients.
format Online
Article
Text
id pubmed-7342521
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73425212020-07-16 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM)with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP). METHODS: From January 2005 to September 2013, a total of 75 patients were treated by metronomic chemotherapy with continuous low-dose cyclophosphamide (50 mg/d) and prednisone (15 mg/d). RESULTS: Among the 75 patients, 2 were lost for follow-up. In the 73 available patients, the overall response was 64.4%, including 2 patients (2.7%) with complete remission (CR), 4 cases (5.5%) very good partial remission (VGPR), and 24 patients (32.9%) partial remission (PR). The median survival was 12 months (1–70 months) with a median onset time of 90 days (16–120) and a median progressive freedom survival of 12 months (1–60). The level of B-type natriuretic peptide in responders declined significantly, as compared to no responders [(336.6±30.3) ng/L vs (906.4±104.8) ng/L, P<0.01]. Common adverse events were as follows: 32 (43.8%) cases of bone marrow suppression, 26 (35.6%) cases of infection, 8 cases of dizzy as well as sleepiness (11.0%), 7 (9.6%) cases of Cushing syndrome, 4 (5.5%) cases of secondary diabetes mellitus, and 3 (4.1%) cases of edema respectively. CONCLUSION: The metronomic chemotherapy of cyclophosphamide combined with prednisone had satisfactory impact on the treatment outcome, including the improvement of cardiac functions and physical capacities, better survival and safety in refractory MM with serious heart failure. It provides a novel regimen for such patients. Editorial office of Chinese Journal of Hematology 2015-03 /pmc/articles/PMC7342521/ /pubmed/25854459 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.03.003 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title_full 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title_fullStr 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title_full_unstemmed 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title_short 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
title_sort 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342521/
https://www.ncbi.nlm.nih.gov/pubmed/25854459
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.03.003
work_keys_str_mv AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá
AT chíxùkǒufúxiǎojìliànghuánlínxiānànliánhépōnísōngzhìliáofùfānánzhìxìngduōfāxìnggǔsuǐliúbànyánzhòngxīngōngnéngbùquánhuànzhěliáoxiàoguānchá